Editor

Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials

GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data

New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...

Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM

AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer

Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

Late-breaking data for Abbott’s Tactiflex Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases

Teva announces positive topline results from phase 2a study in celiac disease for its anti-IL-15 antibody, further validating its pipeline-in-a-product potential

Raziel Therapeutics and Fosun Pharma announce positive phase 3 results for RZL-012 in submental fat reduction, clearing the path to a China NDA filing

Northway Biotech opens (first in Baltics) EUR €61 million cell therapy and personalised medicine CDMO in Vilnius, Lithuania